2018
DOI: 10.3892/or.2018.6429
|View full text |Cite
|
Sign up to set email alerts
|

Oncogenic role of miR‑183‑5p in lung adenocarcinoma: A comprehensive study of qPCR, in�vitro experiments and bioinformatic analysis

Abstract: Despite the fact that previous studies have reported the aberrant expression of miR-183-5p in lung adenocarcinoma (LUAD), the oncogenic role of miR-183-5p in LUAD and its underlying mechanisms have remained elusive. Hence, we attempted to elucidate the clinicopathological significance of miR-183-5p expression in LUAD and identify the biological function of miR-183-5p in LUAD in this study. Meta-analysis of Gene Expression Omnibus (GEO) data, data mining of The Cancer Genome Atlas (TCGA) and real-time quantitat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
16
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
8

Relationship

5
3

Authors

Journals

citations
Cited by 19 publications
(17 citation statements)
references
References 59 publications
1
16
0
Order By: Relevance
“…The cBioPortal database (http://www.cbioportal.org) was mined for mutation profiles of MIR22HG in HCC. 22 The alteration status of MIR22HG in 440 TCGA provisional HCC samples was queried from the OncoPrint module of cBioPortal.…”
Section: Potential Molecular Mechanism Of Mir22hg In Hccmentioning
confidence: 99%
“…The cBioPortal database (http://www.cbioportal.org) was mined for mutation profiles of MIR22HG in HCC. 22 The alteration status of MIR22HG in 440 TCGA provisional HCC samples was queried from the OncoPrint module of cBioPortal.…”
Section: Potential Molecular Mechanism Of Mir22hg In Hccmentioning
confidence: 99%
“…Studies using human-derived samples offering sufficient CASC9 expression data (where the numbers of LUSC and non-cancer cases exceeded 3) in LUSC and non-cancer samples for the calculation of a standardized mean difference (SMD) were included. Basic information, as well as expression and diagnostic data, including accession ID, first author, publication year, country, experiment type, sample type, platform, number of cases in the cancer or non-cancer groups, mean ± SD of CASC9 expression in the cancer or non-cancer groups, true positives, false positives, false negatives and true negatives, were extracted from the included studies according to methods described previously (23). An SMD with the 95% confidence interval (CI) and summarized receiver operating characteristic (SROC) curves were produced for the integrated meta-analysis, consisting of the in-house RT-qPCR data, TCGA data and microarray chip data from ArrayExpress, as described previously (23).…”
Section: Integrated Meta-analysis Of Casc9 Expression In Lusc and Nonmentioning
confidence: 99%
“…The relative miR-182-5p expression level was computed using the method of 2 -Δcq . The statistical analysis for the RT-qPCR was as described previously [39].…”
Section: Methodsmentioning
confidence: 99%
“…Alterations in the expression of miR-182-5p in LUADs, non-LUADs, NSCLC, and non-NSCLC, in addition to the distribution of miR-182-5p in groups of different clinical variables, were calculated to determine the clinical significance of miR-182-5p. The statistical analysis of the miRNA-seq data has been described in detail elsewhere [39]. cases.…”
Section: Methodsmentioning
confidence: 99%